FAPI
9
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
Pancreatic Cancer Diagnosis With FAPI-PET Imaging
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
The Value of 68Ga-FAPI PET/CT for Evaluating Peritoneal Treatment Response
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma